Equities

Alliance Pharma PLC

APH:LSE

Alliance Pharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)37.60
  • Today's Change0.10 / 0.27%
  • Shares traded455.67k
  • 1 Year change-23.65%
  • Beta0.8975
Data delayed at least 20 minutes, as of Jul 05 2024 16:35 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Jul-23
  • 18-Apr-24
  • 16-May-24
  • 20-Jun-24
  • 04-Jul-24
Select bar for recommendation details.
Recommendations04-Jul-24
Buy2
Outperform3
Hold2
Underperform0
Sell0

Share price forecast

The 7 analysts offering 12 month price targets for Alliance Pharma plc have a median target of 50.00, with a high estimate of 85.00 and a low estimate of 42.00. The median estimate represents a 32.98% increase from the last price of 37.60.
High126.1%85.00
Med33.0%50.00
Low11.7%42.00

Dividends

Historical dividend information is not available for Alliance Pharma PLC.
Div growth (TTM)-100.00%
More ▼

Earnings history & estimates

Alliance Pharma plc reported annual 2023 earnings of 4.54 per share on Jun 19, 2024.
Average growth rate+0.01%
More ▼

Revenue history & estimates

Alliance Pharma plc had revenues for the full year 2023 of 180.68m. This was 7.92% above the prior year's results.
Average growth rate+7.98%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.